Put Concerns About Ranitidine and Drug Safety in Perspective
Headlines about a probable carcinogen in some Rx and OTC ranitidine products will raise questions about the safety of generic and brand meds.
The buzz is about N-nitrosodimethylamine (NDMA)...the impurity that first sparked recalls of irbesartan, losartan, and valsartan.
Now FDA is investigating how much NDMA is in ranitidine...whether it poses any risk...and the source. In fact, one independent analysis used high temps to test ranitidine...and the test itself generated NDMA.